Parish Lindsay A, Rele Shyam, Hofmeyer Kimberly A, Luck Brooke B, Wolfe Daniel N
CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USA.
Division of Research, Innovation, and Ventures (DRIVe), Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USA.
Vaccines (Basel). 2025 Jan 14;13(1):73. doi: 10.3390/vaccines13010073.
Over the past few decades, the world has seen a considerable uptick in the number of new and emerging infectious disease outbreaks. The development of new vaccines, vaccine technologies, and platforms are critical to enhance our preparedness for biological threats and prevent future pandemics. Viral vectors can be an important tool in the repertoire of technologies available to develop effective vaccines against new and emerging infectious diseases. In many instances, vaccines may be needed in a reactive scenario, requiring technologies than can elicit rapid and robust immune responses with a single dose. Here, we discuss how viral vector vaccines are utilized in a vaccine portfolio for priority biological threats, some of the challenges in manufacturing viral vector vaccines, the need to strengthen live virus manufacturing capabilities, and future opportunities to capitalize on the use of viral vectors to improve the sustainability of the Biomedical Advanced Research and Development Authority's vaccine portfolio.
在过去几十年里，全球新出现和正在出现的传染病暴发数量显著增加。新型疫苗、疫苗技术和平台的开发对于增强我们应对生物威胁的准备能力以及预防未来大流行至关重要。病毒载体可能是用于开发针对新出现传染病的有效疫苗的可用技术库中的一种重要工具。在许多情况下，可能需要在应对性场景中使用疫苗，这就需要能够通过单剂量引发快速而强劲免疫反应的技术。在此，我们讨论病毒载体疫苗如何用于应对优先生物威胁的疫苗组合中、生产病毒载体疫苗面临的一些挑战、加强活病毒生产能力的必要性，以及利用病毒载体使用来提高生物医学高级研究与发展管理局疫苗组合可持续性的未来机遇。
